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INTRODUCTION
The syndromes of resistance to thyroid hormone (RTH)
are characterized by reduced clinical and biochemical mani-
festations of thyroid hormone action relative to the circulat-
ing hormone levels (1). Since Refetoff et al. initially identi-
fied this syndrome in 1967 (2), over 1,000 cases have been
identified (3). RTH has been associated with mutations in
the thyroid hormone receptor- (THRB) gene. These muta-
tions have, been identified in RTH patients from 300 fami-
lies, and 122 different mutations have been discovered (3).
In 10% of cases of thyroid hormone hyposensitivity, no mu-
tations can be detected in the THRB gene (4).
Only three cases (5, 6) of RTH have been reported in the
Korean literature. All of these reported cases of RTH have
been determined to be the result of point mutations in dif-
ferent regions of the THRB gene. One of these cases presented
as pituitary RTH (5), and the other two presented as gener-
alized RTH (5, 6). However, no insertion mutations have,
been described in Korean RTH patients. Therefore, this report
represents the first observation of generalized RTH associat-
ed with an insertion mutation in the THRB gene in Korea,
found in two individuals from the same family. These results
were confirmed via sequence analysis.
CASE REPORT
A Korean woman initially noticed an enlargement in her
thyroid gland at the age of 43. The thyroid function test re-
vealed elevated free thyroxine (T4) with nonsuppressed thy-
roid stimulating hormone (TSH). She exhibited none of the
signs and symptoms of thyrotoxicosis, which include wast-
ing, agitation, and tachycardia despite high serum levels of
thyroid hormone. Ultrasonography revealed a diffuse goiter
with a nodule in each lobe. Due to the findings of elevated
serum thyroid hormone levels, coupled with increased thy-
roid radioiodide uptake (46% at 24 hr), the patient was pre-
sumed to have primary hyperthyroidism. Therefore, methi-
mazole therapy was administered, and antithyroid drug treat-
ment continued for several months. However, as the patient’s
TSH levels remained slightly elevated, and free T4 and tri-
iodothyronine (T3) were still in excess of upper normal lev-
els after antithyroid drug treatment, RTH was suspected, and
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Thyroid hormone resistance syndrome (RTH) is a rare disorder and is character-
ized by elevated levels of circulating free thyroid hormones, inappropriate secretion
of thyroid stimulating hormone (TSH), and reduced peripheral tissue response to
thyroid hormone. 90% of RTH subjects, when studied at the level of the gene, have
been found to harbor mutations in the thyroid hormone receptor- (THRB) gene.
These affected individuals have been shown to possess a variety of missense muta-
tions, resulting from changes in a single nucleotide in the THRB gene that corre-
sponds to amino acid alternation. However, insertion or deletion mutations in the
THRB gene sequence are quite rare, and have been observed in only a very few
cases. In this study, we describe two such cases, in which two members of the
same family were determined to harbor an insertion mutation in exon 10, and had
also been diagnosed with generalized RTH. This insertion mutation, specifically
the insertion of a cytosine at nucleotide 1358 of the THRB gene, is, to the best of
our knowledge, the first such mutation reported among RTH patients in Korea.
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so the methimazole treatment was discontinued. TSH-secret-
ing adenoma was ruled out on the basis of the following find-
ings: clinical phenotype without manifestations of thyrotox-
icosis, a negative magnetic resonance imaging (MRI) of the
pituitary gland, and the level of the  -subunit of TSH being
within normal range. Her serum level of free T4 was 751.6
pM/L (normal range, 121-322.8), total T3 was 0.058 nM/L
(normal range, 0.012-0.034), and TSH was 1.49 mU/L (nor-
mal range, 0.17-4.05). Thyroid hormone and TSH levels
were measured via radioimmunoassay (RIA) and immunora-
diometric assay (IRMA). Thyroid autoantibodies, including
anti-thyroid peroxidase antibody, anti-thyroglobulin anti-
body, and TSH receptor antibody, were all found to be neg-
ative. Basal metabolic rate, serum cholesterol, and serum sex
hormone binding globulin levels were all normal. She exhib-
ited resistance to thyroid hormone in peripheral and pituitary
tissues. A polymerase chain reaction (PCR) sequencing of
the THRB gene of the patient was subsequently conducted.
Genomic DNA was isolated from the peripheral blood leuko-
cytes of the patient, in accordance with the standard proto-
cols. PCR amplification (PTC-200, MJ Research, Watertown,
MS, U.S.A.) was conducted on seven coding exons (exon 4
to 10) of the THRB gene. The PCR products were then em-
ployed in a direct sequence analysis, using primers identical
to those used for PCR (Table 2), with a BigDye Terminator
system, version 3.0 (ABI Systems, Forester, CA, U.S.A.). The
sequences were analyzed using the computational software,
ABI PRISM Sequence Analysis, version 3.7 (Applied Bio-
systems, Forster City, CA, U.S.A.). In the sequence analysis,
we discovered a mutation in exon 10 of the THRB gene, spe-
cifically, cytosine inserted at position 1358/1359 (1358_
1359insC, Leu454PhefsX11) (Fig. 1). 
During the period in which this patient was still being
evaluated with regard to RTH, the patient also underwent a
subtotal thyroidectomy at another hospital, in which the right
lobe was completely removed and the left lobe was partially
removed. This procedure was necessitated due to the discov-
ery of solid nodules in the thyroid, which, according to the
results of fine needle aspiration cytology, appeared to suggest
*Following administration of 125-150  g/day of T4 over 6 months.
Tg Ab, anti-thyroglobulin antibodies; TPO Ab, anti-thyroid peroxidase
antibodies; TSHR Ab, TSH receptor antibodies; BMR, basal metabolic
rate; SHBG, sex hormone binding globulin; pos, positive; neg, negative. 
Index case
after 
thyroidec-
tomy
Basal
Post-
T4* Her son
Total T3 (0.012-0.034 nM/L) 0.058 - - -
Free T4 (121-321.8 pM/L) 751.6 106.8 763.2 583
TSH (0.17-4.05 mU/L) 1.49 over 100 25.16 6.71
Tg Ab neg neg neg neg
TPO Ab neg neg neg neg
TSHR Ab neg neg neg neg
Goiter pos - - pos
BMR (1,250-1,350 kcal/day) 1,390 1,030 - -
SHBG (16-120 nM/L) 58.7 45.2 - 52.3 
Cholesterol (mg/dL) 191 250 163 156
Resting pulse rate 75 60 83 72
Blood pressure (mmHg) 130/80 100/80 120/80 110/70
Table 1. Clinical and biochemical parameters of the index case
and her son with thyroid hormone resistance syndrome
*The primer sets were designed using Primer3 cgi.0.6 (Steve and Helen,
2000). 
� The sequences were retrieved from Genebank database: NT_
022517.17 (NCBI, Bethesda, MD, USA; http://www.ncbi.nlm.nih.gov).
Primer Sequence*,�(5′ -3′ )
Forward Reverse
Exon
Product
size 
(bp)
4 atctcagcaaaatcttgacaat tacacagctacaacagggatatt 393
5 aaccttagctatagtgtctctttga aatttaaacttaacattgcattctg 262
6 catctcatagttatatggacacaaa taatcaacattccttgaatatgaa 282
7 tgtatcttgggagcatctgt tatcagtaaaatgaggcaataacac 369
8 tgccacataagaactatgataaata ataattaagaataatgcagaaggaa 262
9 gatactgtatgttgttcctgactg aactcaagtgattggaattagc 402
10 ataaaggcctggaattggac agtagtgctgtaggaattatgagaa 360
Table 2. The sequences of primers used in amplification of thy-
roid hormone receptor- gene
A
B
C
CTCTTCCCCCCTTTGTTCTTGGAAGTGTT
CTCTTCCCCCCCTTTGTTCT
1358-1359insC
TTGGAAGTGT
CTCTTCCCCCCTTTGTTCTTGGAAGTGTT
CTCTTCCCCCCCTTTGTTCT TTGGAAGTGT
CTCTTCCCCCCTTTGTTCTTGGAAGTGTT
Fig. 1. The sequence analysis of the thyroid hormone receptor-
(TH- RB) gene in the patient (B) and her son (C) shows an inser-
tion of a C at position 1358/1359 in exon 10. (A) Normal control.562 J.H. Kim, T.S. Park, H.S. Baek, et al.
a follicular neoplasm. The actual pathologic finding of the
tumor was benign adenoma. When the patient revisited our
hospital, she had shown to manifest postprocedural hypothy-
roidism and hypoparathyroidism. She was then placed on
thyroxine, calcium, and vitamin D. The thyroxine dosage
was repeatedly adjusted on the basis of her serum free T4
levels, pre-surgical TSH level, clinical manifestations of thy-
roid hormone excess or deficiency, and tissue indices of thy-
roid hormone action, including basal metabolic rate or sex
hormone-binding globulin levels.
The patient had two children. Her 18-yr-old son and 12-
yr-old daughter also visited our clinic in order to have their
thyroid functions evaluated. Her son was found to have ele-
vated thyroid hormone levels, but was clinically euthyroid.
His serum free T4 level was 583 pM/L (normal range, 121-
321.8), and his TSH level was 6.71 mU/L (normal range,
0.17-4.05). The 99mTechnetium thyroid scan revealed diffuse
enlargement of the thyroid glands, increased uptake, and a
warm nodule. Ultrasonography revealed a diffuse goiter with
a solid nodule in the left lobe, which, upon fine needle aspi-
ration cytology, was suggestive of benign adenoma. Sera from
the mother and her son evidenced identical abnormalities,
with regard to the insertion mutation in nucleotide 1,358/
1,359 in exon 10 (Fig. 1B, C). Her daughter, however, exhib-
ited no abnormalities, with regard to both her thyroid func-
tion tests and her THRB gene sequence. Detailed clinical
information of the index case and of her son are shown in
Table 1.
DISCUSSION
RTH is an inherited condition induced by defects that
reduce the responsiveness of the target tissues to thyroid hor-
mone (1). The incidence of RTH is probably approximately
1 case per 40,000 live births (7). The clinical presentation
of RTH is also known to be highly variable. Whereas most
individuals are clinically euthyroid, some individuals with
RTH may appear to be overtly hypothyroid, while others
may appear thyrotoxic. Furthermore, the same subject with
RTH can manifest signs and symptoms of hypothyroidism
in one tissue, while in another tissue, the findings may be
suggestive of thyrotoxicosis. RTH patients that appear eume-
tabolic or hypothyroid are considered to be suffering from
generalized RTH (GRTH), and those with a hypermetabol-
ic clinical presentation are generally referred to as having
pituitary RTH (3). Finally, the occurrence of isolated periph-
eral tissue resistance to thyroid hormone was reported in a
single patient (8).
Thyroid hormone receptors (TRs) are ligand-dependent
transcription factors, which mediate the biological activities
of T3. TRs are encoded for by the THRA and THRB genes,
which are located on chromosomes 3 and 17, respectively
(3). The alternative splicing of the primary transcripts results
in the formation of four T3-binding proteins ( 1,  2,  3,
and  1), as well as two proteins that do not bind to T3 ( 2
and  3) (9). Although THRA1 and THRB1 are ubiquitously
expressed, THRA1 is expressed primarily in the heart, bone,
and brain, whereas THRB1 is more abundant in the liver,
kidney, and thyroid. THRB2 expression is limited to the pitu-
itary, hypothalamus, retina, and inner ear, and THRB3 ex-
pression has been detected principally in the heart and kid-
ney (7, 11). 90% of RTH subjects, when studied at the level
of the gene, have been found to harbor mutations in the THRB
gene. No mutations have so far been detected in the THRA
gene (3, 9). The THRB gene consists of 10 exons (12); the
aforementioned mutations are located in the last 4 exons,
which code for the hinge region and the ligand-binding do-
main of the receptor. The majority of these mutations result
in a reduction in T3-binding and/or an impairment in trans-
activation. The majority of the previously described muta-
tions are diverse missense mutations that induce single amino
acid substitutions. However, insertion or deletion mutations
of the THRB gene sequence are quite rare, and have been
observed in only a very few cases (13-16).
To the best of our knowledge, this is the second report in
the literature to describe a cytosine insertion mutation at this
position in the THRB gene. Although this insertion muta-
tion is definitely the first such case in the Korean literature,
a similar case was previously reported by Takeda et al. (16).
They described this mutation in the thyroid hormone recep-
tor, which was identified as a cytosine insertion at position
1644, resulting in a frameshift mutation (Leu454PhefsX11)
in a 74-yr old woman presenting with GRTH. A screening
of this woman’s family members resulted in the detection of
similar biochemical abnormalities in two other relatives.
These appeared to be mutations identical to those described
in this paper.
Familial occurrence of RTH has been documented in app-
roximately 75% of cases (3). Inheritance is autosomal domi-
nant (3). Transmission was clearly recessive in only one fam-
ily (2, 17). Consanguinity in a family with dominant inher-
itance of RTH has produced a homozygous child with severe
resistance to the hormone who died at the age of 7 yr (18).
Patients exhibiting a frameshift mutation from codon 454
to 463 can be considered to have GRTH, and appear to trans-
mit the condition in an autosomal dominant manner, accord-
ing to two reports (the present case, 16).
Another interesting characteristic of our two cases involves
the thyroid nodules found prior to surgery. Thyroid enlarge-
ment in RTH patients tends to be diffuse, whereas nodular
changes and gross asymmetry are more common features of
recurrent goiters after surgery (1). Taniyama et al. (19) has
reported only one case of GRTH that was accompanied by a
toxic multinodular goiter and thyroid microcarcinoma. A
molecular examination of this case revealed a R429Q muta-
tion in the THRB gene. This is one of the mutations that is
usually associated with a pituitary resistance phenotype. InGeneralized RTH with Insertion Mutation in THRB gene 563
our case, the solid nodule in the index case upon fine needle
aspiration cytology was suggestive of follicular neoplasm.
The postsurgical pathologic examination confirmed the exis-
tence of benign adenoma within the thyroid gland and found
no evidence of malignancy. The etiology of nodular goiters
has yet to be clearly elucidated, but continuous growth stim-
ulation by thyrotrophic substances including TSH, thyroid
growth stimulating immunoglobulin, and IGF-1, is believed
to be involved in cell proliferation (20). Continuous stimu-
lation by excess TSH may be a causative factor in some cases
of RTH. 
In this study, we have described a 1358_1359 insC muta-
tion in exon 10 occurring in two members of the same fam-
ily, both of whom were diagnosed with generalized RTH.
This mutation has not been observed in any other RTH pati-
ents in Korea, but has been postulated to be the cause of RTH
in the family described in this study.
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